Arrowhead Pharmaceuticals (NASDAQ:ARWR) Sets New 1-Year Low at $18.61

Shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) hit a new 52-week low on Tuesday . The company traded as low as $18.61 and last traded at $18.66, with a volume of 77258 shares changing hands. The stock had previously closed at $19.37.

Wall Street Analyst Weigh In

A number of equities analysts have recently weighed in on the company. StockNews.com raised Arrowhead Pharmaceuticals to a “sell” rating in a report on Thursday, August 1st. B. Riley reaffirmed a “buy” rating and issued a $55.00 price objective on shares of Arrowhead Pharmaceuticals in a research report on Monday, August 12th. HC Wainwright reiterated a “buy” rating and set a $60.00 target price on shares of Arrowhead Pharmaceuticals in a research note on Tuesday, September 3rd. The Goldman Sachs Group started coverage on Arrowhead Pharmaceuticals in a report on Wednesday, June 5th. They issued a “neutral” rating and a $31.00 price objective for the company. Finally, Royal Bank of Canada restated an “outperform” rating and set a $42.00 price objective on shares of Arrowhead Pharmaceuticals in a research note on Thursday, September 26th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and six have issued a buy rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $43.25.

Arrowhead Pharmaceuticals Price Performance

The company has a market capitalization of $2.29 billion, a price-to-earnings ratio of -4.30 and a beta of 0.96. The business has a fifty day moving average price of $23.57 and a 200 day moving average price of $24.77.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last announced its earnings results on Thursday, August 8th. The biotechnology company reported ($1.38) EPS for the quarter, missing the consensus estimate of ($0.58) by ($0.80). Arrowhead Pharmaceuticals had a negative return on equity of 152.95% and a negative net margin of 163.32%. Arrowhead Pharmaceuticals’s revenue was down 100.0% compared to the same quarter last year. During the same period in the prior year, the firm posted ($0.96) EPS. Research analysts anticipate that Arrowhead Pharmaceuticals, Inc. will post -4.31 earnings per share for the current year.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the company. Fifth Third Bancorp lifted its holdings in Arrowhead Pharmaceuticals by 42.5% in the 2nd quarter. Fifth Third Bancorp now owns 1,186 shares of the biotechnology company’s stock valued at $31,000 after acquiring an additional 354 shares during the last quarter. Neo Ivy Capital Management acquired a new stake in Arrowhead Pharmaceuticals during the fourth quarter valued at approximately $41,000. Headlands Technologies LLC boosted its holdings in Arrowhead Pharmaceuticals by 7,696.8% during the first quarter. Headlands Technologies LLC now owns 2,417 shares of the biotechnology company’s stock worth $69,000 after buying an additional 2,386 shares in the last quarter. Meeder Asset Management Inc. grew its position in Arrowhead Pharmaceuticals by 4,629.2% in the second quarter. Meeder Asset Management Inc. now owns 3,405 shares of the biotechnology company’s stock worth $88,000 after buying an additional 3,333 shares during the last quarter. Finally, nVerses Capital LLC bought a new position in shares of Arrowhead Pharmaceuticals in the second quarter valued at $96,000. Institutional investors own 62.61% of the company’s stock.

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.